National Cancer Institute; Notice of Meeting, 50033-50034 [2020-17906]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 159 / Monday, August 17, 2020 / Notices
44. Jeffrey Balch, Chicago, Illinois, Court
of Federal Claims No: 20–0872V
45. Elaine Montana, Boston,
Massachusetts, Court of Federal
Claims No: 20–0873V
46. Susan Greenberg-Folkman, Los
Ranchos, New Mexico, Court of
Federal Claims No: 20–0874V
47. Wanda Oliver, Boston,
Massachusetts, Court of Federal
Claims No: 20–0877V
48. Jerry L. Bailey, Moline, Illinois,
Court of Federal Claims No: 20–
0878V
49. Jasmine Dede, Elmont, New York,
Court of Federal Claims No: 20–
0880V
50. Domenica Foster, Medford, New
Jersey, Court of Federal Claims No:
20–0882V
51. Eric Simmons, Boston,
Massachusetts, Court of Federal
Claims No: 20–0884V
52. Gesdia Kelly, Phoenix, Arizona,
Court of Federal Claims No: 20–
0885V
53. Mark Thomas on behalf of Z. T.,
Loxahatchee, Florida, Court of
Federal Claims No: 20–0886V
54. John Timothy Hamilton, Boston,
Massachusetts, Court of Federal
Claims No: 20–0887V
55. Thomas Bierbaum, Edina,
Minnesota, Court of Federal Claims
No: 20–0888V
56. Shaun Gladders, New Lenox,
Illinois, Court of Federal Claims No:
20–0891V
57. Kyle Bolick, Omaha, Nebraska,
Court of Federal Claims No: 20–
0893V
58. Brandon Robison, Yakima,
Washington, Court of Federal
Claims No: 20–0896V
59. Christopher Diane Lewis, Dallas,
Texas, Court of Federal Claims No:
20–0898V
60. Jan Koonce, Boston, Massachusetts,
Court of Federal Claims No: 20–
0899V
61. Paula Doze, Boston, Massachusetts,
Court of Federal Claims No: 20–
0900V
62. Raymond Balcer, Boston,
Massachusetts, Court of Federal
Claims No: 20–0901V
63. James Harkins, Hamilton, Montana,
Court of Federal Claims No: 20–
0902V
64. Sapna Patel, Houston, Texas, Court
of Federal Claims No: 20–0903V
65. Russell Ramsey, Oklahoma City,
Oklahoma, Court of Federal Claims
No: 20–0904V
66. Allison Romansky, Baltimore,
Maryland, Court of Federal Claims
No: 20–0907V
67. Constance Nichols, Watertown, New
York, Court of Federal Claims No:
20–0912V
VerDate Sep<11>2014
17:13 Aug 14, 2020
Jkt 250001
68. Georgina Ransford, Washington,
District of Columbia, Court of
Federal Claims No: 20–0914V
69. Jason Barrow, Washington, District
of Columbia, Court of Federal
Claims No: 20–0915V
70. Christopher Dougherty, Washington,
District of Columbia, Court of
Federal Claims No: 20–0916V
71. James Kincaid, Washington, District
of Columbia, Court of Federal
Claims No: 20–0917V
72. Ashley Nore, Huntsville, Alabama,
Court of Federal Claims No: 20–
0919V
73. Tawana T. Morrison, Rochester,
New York, Court of Federal Claims
No: 20–0921V
74. Theresa Pistochini, Washington,
District of Columbia, Court of
Federal Claims No: 20–0922V
75. Eric Newak, Coer d’Alene, Idaho,
Court of Federal Claims No: 20–
0923V
76. Jodi Solem, Washington, District of
Columbia, Court of Federal Claims
No: 20–0925V
77. Jodi Solem, Washington, District of
Columbia, Court of Federal Claims
No: 20–0927V
78. Ayon Wen-Waldron on behalf of The
Estate of Darryl Waldron,
Washington, District of
ColumbiaCourt of Federal Claims
No: 20–0928V
79. Samantha Ivers, Elk Grove Village,
Illinois, Court of Federal Claims No:
20–0929V
80. Amber Bob on behalf of G. B.,
Phoenix, Arizona, Court of Federal
Claims No: 20–0931V
81. Ijeoma Chukwudum, Houston,
Texas, Court of Federal Claims No:
20–0936V
82. Carl Carnes, Beverly Hills,
California, Court of Federal Claims
No: 20–0937V
83. Mary Ward, Fontana, California,
Court of Federal Claims No: 20–
0938V
84. Olivia Renchen, Beverly Hills,
California, Court of Federal Claims
No: 20–0939V
85. Darla Conley, Beverly Hills,
California,Court of Federal Claims
No: 20–0940V
86. Linda Howard, Dresher,
Pennsylvania, Court of Federal
Claims No: 20–0941V
87. Erin Mattheis, Beverly Hills,
California, Court of Federal Claims
No: 20–0942V
88. Lillie Johnson, Dresher,
Pennsylvania, Court of Federal
Claims No: 20–0943V
89. Theresa Cristoph, Richmond,
Virginia, Court of Federal Claims
No: 20–0945V
90. Jessica Mott on behalf of Lola
Crawford, New York, New York,
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
50033
Court of Federal Claims No: 20–
0947V
91. Annika Olsen-Santoro, Pasadena,
California, Court of Federal Claims
No: 20–0948V
92. Randy Moore, Washington, District
of Columbia, Court of Federal
Claims No: 20–0949V
[FR Doc. 2020–17936 Filed 8–14–20; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health Amended; Notice
of Meeting
Notice is hereby given of a change in
the meeting of the Council of Councils,
September 11, 2020, 08:15 a.m. to 04:00
p.m., National Institutes of Health,
Natcher Building, Building 45 Room D,
C1/C2 and G1/G2, 45 Center Drive,
Bethesda, MD 20892 which was
published in the Federal Register on
December 16, 2019, 84 FR 68467.
The meeting notice is amended to
change the open and closed session
meeting times as follows: The open
session will now be held from 10:15
a.m. to 1:00 p.m. and from 2:15 p.m. to
4:55 p.m. with the closed session held
from 1:00 p.m. to 2:00 p.m. This notice
is also being amended to change the
meeting location from National
Institutes of Health, Natcher Building,
Building 45 Room D, C1/C2 and G1/G2,
45 Center Drive, Bethesda, MD 20892 to
a virtual meeting. The url link to this
meeting can be found at: https://
videocast.nih.gov/. Any member of the
public may submit written comments no
later than 15 days after the meeting.
Dated: August 12, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–17907 Filed 8–14–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual
meeting and is open to the public as
E:\FR\FM\17AUN1.SGM
17AUN1
50034
Federal Register / Vol. 85, No. 159 / Monday, August 17, 2020 / Notices
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting
should notify the Contact Person listed
below in advance of the meeting. The
meeting will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: September 1, 2020.
Open: 1:00 p.m. to 5:45 p.m.
Agenda: NCAB Subcommittee Meetings—
Subcommittee on Planning and Budget; Ad
Hoc Subcommittee on Experimental
Therapeutics; Ad Hoc Subcommittee on
Population Science, Epidemiology and
Disparities; and Ad Hoc Subcommittee on
Global Cancer Research.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meetings).
Instructions regarding access to the virtual
Subcommittee Meetings will be posted at:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm.
Name of Committee: National Cancer
Advisory Board.
Date: September 2, 2020.
Open: 1:00 p.m. to 3:15 p.m.
Agenda: Director’s and Program reports
and presentations; business of the Board.
Closed: 3:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Executive Secretary Division of Extramural
Activities, National Cancer Institute—Shady
Grove, National Institutes of Health, 9609
Medical Center Drive, 7th Floor, Room
7W444 Bethesda, MD 20892, 240–276–6340,
grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda,
VerDate Sep<11>2014
17:13 Aug 14, 2020
Jkt 250001
instructions for accessing the virtual NCAB
meetings, and any additional information for
the meetings will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 12, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–17906 Filed 8–14–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual
meeting and is open to the public, as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting,
should notify the Contact Person listed
below in advance of the meeting. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov/).
A portion of this meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: September 10, 2020.
Closed: 11:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate grant
applications.
Open: 12:45 p.m. to 4:30 p.m.
Agenda: Presentations and other business
of the Council.
Place: National Institutes of Health,
National Institute on Drug Abuse,
Neurosciences Center Building, 6001
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, NSC, Room 5274, MSC 9591,
Rockville, MD 20892, 301–443–6487,
sweiss@nida.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: August 11, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–17817 Filed 8–14–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS–CoV–2) and
Coronavirus Disease 2019 (COVID–19).
Date: August 27, 2020.
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 85, Number 159 (Monday, August 17, 2020)]
[Notices]
[Pages 50033-50034]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17906]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual meeting and is open to the
public as
[[Page 50034]]
indicated below. Individuals who plan to view the virtual meeting and
need special assistance or other reasonable accommodations to view the
meeting should notify the Contact Person listed below in advance of the
meeting. The meeting will be videocast and can be accessed from the NIH
Videocasting and Podcasting website (https://videocast.nih.gov/).
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: September 1, 2020.
Open: 1:00 p.m. to 5:45 p.m.
Agenda: NCAB Subcommittee Meetings--Subcommittee on Planning and
Budget; Ad Hoc Subcommittee on Experimental Therapeutics; Ad Hoc
Subcommittee on Population Science, Epidemiology and Disparities;
and Ad Hoc Subcommittee on Global Cancer Research.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meetings).
Instructions regarding access to the virtual Subcommittee
Meetings will be posted at: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm.
Name of Committee: National Cancer Advisory Board.
Date: September 2, 2020.
Open: 1:00 p.m. to 3:15 p.m.
Agenda: Director's and Program reports and presentations;
business of the Board.
Closed: 3:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Executive Secretary
Division of Extramural Activities, National Cancer Institute--Shady
Grove, National Institutes of Health, 9609 Medical Center Drive, 7th
Floor, Room 7W444 Bethesda, MD 20892, 240-276-6340,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm, where an agenda, instructions for accessing the
virtual NCAB meetings, and any additional information for the
meetings will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: August 12, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-17906 Filed 8-14-20; 8:45 am]
BILLING CODE 4140-01-P
